Johnson & Johnson is trading 3.1% up today at $273.75 after announcing a $5.5 billion agreement to resolve outstanding ovarian talc litigation, removing a major legal overhang.
- The settlement aims to resolve long-standing legal disputes, providing much-needed clarity on a significant financial liability.
- The stock's performance is further supported by a broad healthcare sector rally driven by strong institutional demand and AI-related optimism.